PT-141 10mg 10mL Vial
£295.00
MOA
- Melanocortin Receptor Activation:
- PT-141 is a selective melanocortin receptor agonist that primarily targets melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors located within the central nervous system. Activation of these receptors modulates neuroendocrine circuits involved in sexual desire and arousal.
- Central Nervous System Pathways:
- Unlike phosphodiesterase inhibitors that act via peripheral vasodilation, PT-141 operates centrally by influencing hypothalamic pathways responsible for sexual motivation and behavior. This mechanism directly enhances sexual drive independent of vascular function.
- Dopaminergic and Oxytocinergic Modulation:
- Stimulation of MC4R receptors enhances dopaminergic neurotransmission and promotes the release of oxytocin—both critical mediators of sexual arousal, bonding, and reward. This neurochemical modulation amplifies sexual desire and positive affective responses.
- Autonomic and Neuroendocrine Regulation:
- PT-141 influences sympathetic nervous system output and integrates neuroendocrine signals that coordinate arousal responses. These effects result in heightened sexual readiness and improved central activation of arousal networks.
- Distinct Mechanistic Profile:
- Through its central melanocortin-mediated mechanism, PT-141 provides a unique therapeutic pathway for addressing hypoactive sexual desire and arousal disorders. Its independence from nitric oxide–mediated vasodilation makes it effective in both male and female patients, including those unresponsive to PDE5 inhibitors.
More Information
- Disclaimer: For Research Purposes Only – All products on this site are for Research and Development use only. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. Celia Health is a supplier of research-use chemicals manufactured in a CGMP facility in the US. Celia Health is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act.
